Trial Profile
To Find the Best Dose of pVGI.1(VEGF2) to Benefit Angina Patients When Given With an Experimental Injection Catheter.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2010
Price :
$35
*
At a glance
- Drugs Vascular endothelial growth factor-2 gene therapy (Primary)
- Indications Angina pectoris
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms GENASIS
- Sponsors Corautus Genetics
- 16 Oct 2006 Status change
- 24 Jan 2006 New trial record.